This is the authors' abstract. We don't add key points for this paper.
Background: Early breast cancer(eBC) , in part, is a curable disease.Recurrence and metastasis are the main causes of such patients mortality. Although post-operative adjuvant therapy for breast cancer has made great strides, challenges remain and new therapeutic approaches are needed. Cellular immunotherapy(CIT) provides a promising new therapeutic to the management of eBC.This study aims to assess the efficacy and safty of sequential CIT after chemoradiotherapy in patients with post-mastectomy eBC as well as exploring the potential beneficiaries of CIT.Methods: From January 2010 to December 2014, 723 patients with post-mastectomy eBC were included in this retrospective study: 118 caces underwent CIT in addition to initial therapy; a further 605 cases received initial therapy only,such as chemoradiotherapy,endocrine therapy and targeted therapy, etc.Results: A comparison of the 5-year survival curves shows that the 5-year disease free survival(DFS) of patients in the CIT group was signifificantly higher than in the control group(86.44% vs 78.51%, P=0.045).The multivariate analysis identified CIT as a noteworthy independent risk factor for DFS(P=0.027, HR=0.552(0.325-0.935 )). Subgroup analysis revealed that adjuvant CIT markedly increased the DFS rate of patients with axillary lymph node metastasis and tumor–node–metastasis(TNM)stage III. None of the patients enrolled in the CIT group discontinued CIT due to adverse reactions.Conclusions: Our study suggests that CIT was a species of safe and effective mode of treatment improving the DFS for patients with post-mastectomy eBC, especially those with lymph node metastasis and advanced TNM stage, and the toxicity was tolerable and consisted primarily of reversible hyperthermia.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2022) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: